911227-51-5Relevant articles and documents
Potent, orally bioavailable delta opioid receptor agonists for the treatment of pain: Discovery of N,N-diethyl-4-(5-hydroxyspiro-[chromene-2, 4′-piperidine]-4-yl)benzamide (ADL5859)
Le Bourdonnec, Bertrand,Windh, Rolf T.,Ajello, Christopher W.,Leister, Lara K.,Gu, Minghua,Chu, Guo-Hua,Tuthill, Paul A.,Barker, William M.,Koblish, Michael,Wiant, Daniel D.,Graczyk, Thomas M.,Belanger, Serge,Cassel, Joel A.,Feschenko, Marina S.,Brogdon, Bernice L.,Smith, Steven A.,Christ, David D.,Derelanko, Michael J.,Kutz, Steve,Little, Patrick J.,DeHaven, Robert N.,DeHaven-Hudkins, Diane L.,Dolle, Roland E.
supporting information; experimental part, p. 5893 - 5896 (2009/10/17)
Selective δ opioid receptor agonists are promising potential therapeutic agents for the treatment of various types of pain conditions. A spirocyclic derivative was identified as a promising hit through screening. Subsequent lead optimization identified compound 20 (ADL5859) as a potent, selective, and orally bioavailable δ agonist. Compound 20 was selected as a clinical candidate for the treatment of pain.
SPIROCYCLIC HETEROCYCLIC DERIVATIVES AND METHODS OF THEIR USE
-
Page/Page column 252, (2008/06/13)
Spirocyclic heterocyclic derivatives, pharmaceutical compositions containing these compounds, and methods for their pharmaceutical use are disclosed. In certain embodiments, the spirocyclic heterocyclic derivatives are ligands of the δ opioid receptor and
